Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignace Vergote

Showing results (321-330 of 578) with videos related to

Pageof 58
Sort By:
Gynecologic Oncology|March 6, 2024
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancerDebra L Richardson, Kathleen N Moore, Ignace Vergote, et al.
Gynecologic Oncology|June 7, 2015
Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology GroupIgnace Vergote, Philip Debruyne, Frédéric Kridelka, et al.
Gynecologic Oncology|October 3, 2022
A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancerPanagiotis A Konstantinopoulos, Jung-Min Lee, Bo Gao, et al.
Gynecologic Oncology|October 5, 2014
Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trialChee Khoon Lee, Sarah Lord, Tami Grunewald, et al.
Gynecologic Oncology|October 16, 2012
Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer--a study by the OVCAD consortiumAndreas Melmer, Linda Fineder, Claudia Lamina, et al.
International Journal of Cancer|October 29, 2011
Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancerFrederik Marmé, Thomas Hielscher, Sarah Hug, et al.
International Journal of Cancer|July 5, 2020
miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patientsKonstantina Panoutsopoulou, Margaritis Avgeris, Paraskevi Magkou, et al.
Cancer Research|February 20, 2003
The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosisLiu-Ying Luo, Dionyssios Katsaros, Andreas Scorilas, et al.
Cancer|April 11, 2016
Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapyUrsula A Matulonis, Philipp Harter, Charlie Gourley, et al.
Plos One|December 3, 2015
Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women's CancersThomas E Bartlett, Allison Jones, Ellen L Goode, et al.
Pageof 58

Showing results (321-330 of 578) with videos related to

Sort By:
Pageof 58
Gynecologic Oncology|March 6, 2024
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancerDebra L Richardson, Kathleen N Moore, Ignace Vergote, et al.
Gynecologic Oncology|June 7, 2015
Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology GroupIgnace Vergote, Philip Debruyne, Frédéric Kridelka, et al.
Gynecologic Oncology|October 3, 2022
A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancerPanagiotis A Konstantinopoulos, Jung-Min Lee, Bo Gao, et al.
Gynecologic Oncology|October 5, 2014
Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trialChee Khoon Lee, Sarah Lord, Tami Grunewald, et al.
Gynecologic Oncology|October 16, 2012
Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer--a study by the OVCAD consortiumAndreas Melmer, Linda Fineder, Claudia Lamina, et al.
International Journal of Cancer|October 29, 2011
Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancerFrederik Marmé, Thomas Hielscher, Sarah Hug, et al.
International Journal of Cancer|July 5, 2020
miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patientsKonstantina Panoutsopoulou, Margaritis Avgeris, Paraskevi Magkou, et al.
Cancer Research|February 20, 2003
The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosisLiu-Ying Luo, Dionyssios Katsaros, Andreas Scorilas, et al.
Cancer|April 11, 2016
Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapyUrsula A Matulonis, Philipp Harter, Charlie Gourley, et al.
Plos One|December 3, 2015
Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women's CancersThomas E Bartlett, Allison Jones, Ellen L Goode, et al.
Pageof 58